ReviewCurrent hematologic malignancy reports2016
PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas.
Review in Current hematologic malignancy reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- Molecular Mechanisms of Diffuse Large B-Cell Lymphoma and the Complexities of Tumor Development.Saudi medical journal · 2026Review
- Whole-body magnetic resonance imaging provides accurate staging of diffuse large B-cell lymphoma, but is less preferred by patients.World journal of radiology · 2025Article
- Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma.Nature communications · 2025Article
- Clinical and Diagnostic Challenges in Primary Splenic Lymphomas: When is Splenectomy Necessary to Differentiate SMZL from DLBCL?European journal of case reports in internal medicine · 2025Article
- FDG-PET/CT Provides Clues on Bone Marrow Involvement in Follicular Lymphoma and Carries Important Prognostic Information.Journal of Cancer · 2023Article
- Interim and end-of-treatment PET-CT suffers from high false-positive rates in DLBCL: Biopsy is needed prior to treatment decisions.Cancer medicine · 2021Article
- 5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients.Clinical epigenetics · 2021Article
- Imaging Features and Prognostic Value of FDG PET/CT in Patients with Intravascular Large B-Cell Lymphoma.Cancer management and research · 2021Article
- Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information.Blood advances · 2020Article
- Non-traumatic splenic rupture - a rare first presentation of diffuse large B-cell lymphoma and a review of the literature.BMC cancer · 2018Review
- Evolution of lymphoma staging and response evaluation: current limitations and future directions.Nature reviews. Clinical oncology · 2017Article
- Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials.Drug design, development and therapy · 2017Article
- FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?Haematologica · 2016Article
- Modifying therapy in patients with advanced Hodgkin's lymphoma by integrating early metabolic response by interim PET-CT.Annals of translational medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Positron emission tomography (PET)-CT was recommended in updated international guidelines for staging/restaging of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). In FL, PET was previously regarded as a research application only. This review concentrates on new publications related to PET in these diseases. In DLBCL, PET appears appropriate for staging using prognostic indices established with CT and baseline PET parameters, e.g. metabolic tumour volume, are prognostic of outcome. Early complete metabolic response (CMR) predicts end-of-treatment CMR with excellent prognosis. Patients without CMR at interim should not have treatment altered, but have a worse prognosis, and patients with other high risk features may need closer monitoring. The end-of-treatment scan is confirmed as the standard for remission assessment using Deauville criteria, which are also predictive for patients undergoing ASCT. In FL, PET is more sensitive for staging than CT but misses bone marrow involvement. PET-CT identifies patients at risk of progression after induction chemotherapy better than CT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.